Literature DB >> 14516126

Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8.

T M Bull1, C D Cool, A E Serls, P R Rai, J Parr, J M Neid, M W Geraci, T B Campbell, N F Voelkel, D B Badesch.   

Abstract

Primary pulmonary hypertension (PPH) and Castleman's disease (CD) are rare conditions infrequently encountered in clinical practice. In this paper, two patients diagnosed with both of these diseases are reported. The authors speculate that rather than being a chance occurrence, these conditions are linked by a common angio-proliferative mechanism. Therefore, an association between infection with the human herpesvirus-8 and the diseases of PPH and CD was sought. Evidence of human herpesvirus-8 infection was found in the lung tissue and, specifically, in the plexiform lesions from one of the patients.

Entities:  

Mesh:

Year:  2003        PMID: 14516126     DOI: 10.1183/09031936.03.00006903

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  BK and JC polyomaviruses are not associated with idiopathic pulmonary fibrosis.

Authors:  G W Procop; D J Kohn; J E Johnson; H J Li; J E Loyd; B Yen-Lieberman; Y W Tang
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

2.  Functional divergence of Kaposi's sarcoma-associated herpesvirus and related gamma-2 herpesvirus thymidine kinases: novel cytoplasmic phosphoproteins that alter cellular morphology and disrupt adhesion.

Authors:  Michael B Gill; Jo-Ellen Murphy; Joyce D Fingeroth
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells.

Authors:  Todd M Bull; Christina A Meadows; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; Serge P Nana-Sinkam; Thomas B Campbell; Mark W Geraci
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

4.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

5.  The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease.

Authors:  Yoh Arita; Yasushi Sakata; Takao Sudo; Tetsuo Maeda; Ken Matsuoka; Keito Tamai; Kaori Higuchi; Wataru Shioyama; Yoshikazu Nakaoka; Yuzuru Kanakura; Keiko Yamauchi-Takihara
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 6.  A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Authors:  Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

Review 7.  The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.

Authors:  Nada Kherbeck; Mathieu C Tamby; Guillaume Bussone; Hanadi Dib; Frederic Perros; Marc Humbert; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

8.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

Review 9.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

10.  Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Stephen L Archer; Albert Defelice; Steven Evans; Monica Fiszman; Thomas Martin; Muriel Saulnier; Marlene Rabinovitch; Ralph Schermuly; Duncan Stewart; Hubert Truebel; Gennyne Walker; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.